Ajinomoto AminoScience Launches Innovative Peptide Synthesis And Manufacturing Service
Ajinomoto Aminoscience LLC announced recently the launch of AjiPhase, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.
AjiPhase enables the use of a single peptide synthesis methodology throughout therapeutic peptide development, negating the need to transition between solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) methodologies as peptide requirements increase. The use of a single synthetic methodology eliminates the need for additional development time required in switching from solid to liquid phase methods and also removes the need to revalidate the impurity profile when transitioning synthetic methods.
"For scientists in pharmaceutical and biotechnology product development, AjiPhase gives the benefits of SPPS with its efficient removal of un-reacted reagents," stated Dr. Dwayne Allen, business manager of biotechnology, Ajinomoto AminoScience. "Those in R&D and business development roles appreciate the cost advantage of larger scale synthesis, as it is not limited by starting material linked to a solid support. This greatly increases the commercial viability of peptides, gives companies access to higher-purity peptides and reduces development time."
By leveraging the best of both solid and liquid phases, AjiPhase provides a financially-feasible way to advance complex peptides through the development pipeline in a timely manner. Combining the benefits of SPPS with the convergent synthesis ability of LPPS, AjiPhase makes more complex peptides accessible that may have been too impractical or expensive to manufacture.
"Long-recognized as the leader in amino acid R&D and production technology, Ajinomoto continually pushes ahead with new technology and service offerings. With the launch of AjiPhase, pharmaceutical and biotechnology companies of all sizes now have new resource for their peptide needs as well as a partner with experience in process development, QA/QC, analytical services and regulatory support," stated Jack Heaton, president of Ajinomoto AminoScience, LLC.
For more information on this new service offering, please visit www.ajiphase.com.
About Ajinomoto AminoScience, LLC
Ajinomoto is the leading supplier of pharmaceutical and research-grade amino acids in the US and throughout the world. Leveraging its unrivaled foundation of more than 50 years of experience identifying, refining, and marketing amino acids, Ajinomoto AminoScience, LLC (AAS) continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields. Building on its legacy, AAS has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis. These new processes enable pharmaceutical and bio-tech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce. The Corynex Recombinant Protein Expression System is a streamlined, more efficient process to produce complex human proteins for pharmaceutical use using a specially-developed gram-positive bacterium, Corynebacterium glutamicum. Ajinomoto AminoScience, LLC is a part of Ajinomoto USA Inc., a wholly-owned subsidiary of Ajinomoto Co., Inc. For more information visit http://www.ajiaminoscience.com/Default.aspx.
SOURCE: Ajinomoto AminoScience, LLC